NO342966B1 - Fremgangsmåter for behandling av immunforstyrrelser assosiert med organtransplantasjon med løselige CTLA4-mutantmolekyler - Google Patents

Info

Publication number

NO342966B1

NO342966B1 NO20075078A NO20075078A NO342966B1 NO 342966 B1 NO342966 B1 NO 342966B1 NO 20075078 A NO20075078 A NO 20075078A NO 20075078 A NO20075078 A NO 20075078A NO 342966 B1 NO342966 B1 NO 342966B1

Authority

NO

Norway

Prior art keywords

molecule

ctla4

use according

ctla4 mutant

visit

Prior art date

2005-04-06

Links

• Espacenet
• Global Dossier
• Discuss

• 238000002054 transplantation Methods 0.000 title claims abstract description 84
• 208000026278 immune system disease Diseases 0.000 title claims abstract description 38
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title claims abstract description 26
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title claims abstract 23
• 210000000056 organ Anatomy 0.000 title claims description 32
• 238000000034 method Methods 0.000 title description 65
• 238000011282 treatment Methods 0.000 claims abstract description 102
• 230000001154 acute effect Effects 0.000 claims description 77
• 210000004027 cell Anatomy 0.000 claims description 68
• 210000003734 kidney Anatomy 0.000 claims description 50
• 206010020772 Hypertension Diseases 0.000 claims description 47
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 47
• 108060003951 Immunoglobulin Proteins 0.000 claims description 43
• 102000018358 immunoglobulin Human genes 0.000 claims description 43
• 235000004279 alanine Nutrition 0.000 claims description 39
• 238000012423 maintenance Methods 0.000 claims description 39
• 210000002966 serum Anatomy 0.000 claims description 39
• 235000003704 aspartic acid Nutrition 0.000 claims description 38
• CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 38
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 38
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 32
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 31
• 229960004866 mycophenolate mofetil Drugs 0.000 claims description 30
• 229930182817 methionine Natural products 0.000 claims description 29
• 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 26
• 239000003795 chemical substances by application Substances 0.000 claims description 24
• 239000003246 corticosteroid Substances 0.000 claims description 23
• 206010048748 Graft loss Diseases 0.000 claims description 22
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 21
• 235000013922 glutamic acid Nutrition 0.000 claims description 21
• 239000004220 glutamic acid Substances 0.000 claims description 21
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 21
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
• 229960004669 basiliximab Drugs 0.000 claims description 19
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 18
• 229960002930 sirolimus Drugs 0.000 claims description 18
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 17
• 201000008827 tuberculosis Diseases 0.000 claims description 16
• 229960001334 corticosteroids Drugs 0.000 claims description 14
• 210000004698 lymphocyte Anatomy 0.000 claims description 14
• 239000004471 Glycine Substances 0.000 claims description 13
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 13
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 12
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 12
• 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 12
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 12
• 241000282693 Cercopithecidae Species 0.000 claims description 10
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 10
• 239000004472 Lysine Substances 0.000 claims description 10
• 229960004584 methylprednisolone Drugs 0.000 claims description 10
• 229960004618 prednisone Drugs 0.000 claims description 10
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 10
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 9
• 108010036949 Cyclosporine Proteins 0.000 claims description 9
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 9
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 9
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 9
• 229960005205 prednisolone Drugs 0.000 claims description 9
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 9
• 206010049993 Cardiac death Diseases 0.000 claims description 8
• 206010011906 Death Diseases 0.000 claims description 8
• 239000007787 solid Substances 0.000 claims description 8
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 7
• 208000006011 Stroke Diseases 0.000 claims description 7
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 7
• 230000037396 body weight Effects 0.000 claims description 7
• 239000003112 inhibitor Substances 0.000 claims description 6
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 6
• 206010052779 Transplant rejections Diseases 0.000 claims description 5
• 229960001265 ciclosporin Drugs 0.000 claims description 5
• 229960002806 daclizumab Drugs 0.000 claims description 5
• 235000005911 diet Nutrition 0.000 claims description 5
• 230000037213 diet Effects 0.000 claims description 5
• 208000036981 active tuberculosis Diseases 0.000 claims description 4
• 229930182912 cyclosporin Natural products 0.000 claims description 4
• 239000012636 effector Substances 0.000 claims description 4
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
• 231100000355 lymphocytotoxic Toxicity 0.000 claims description 4
• 230000001391 lymphocytotoxic effect Effects 0.000 claims description 4
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 4
• 229960001967 tacrolimus Drugs 0.000 claims description 4
• OQUXVPJVBSENGK-QXMHVHEDSA-N (z)-2,5-dicyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]pent-2-enamide Chemical compound N#CCCC(/O)=C(\C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 OQUXVPJVBSENGK-QXMHVHEDSA-N 0.000 claims description 3
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
• 102000006395 Globulins Human genes 0.000 claims description 3
• 108010044091 Globulins Proteins 0.000 claims description 3
• 206010023439 Kidney transplant rejection Diseases 0.000 claims description 3
• 230000001494 anti-thymocyte effect Effects 0.000 claims description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
• 229960005167 everolimus Drugs 0.000 claims description 3
• 229960000556 fingolimod Drugs 0.000 claims description 3
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
• 229960000951 mycophenolic acid Drugs 0.000 claims description 3
• 229960004641 rituximab Drugs 0.000 claims description 3
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
• VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
• 208000031886 HIV Infections Diseases 0.000 claims description 2
• 208000037357 HIV infectious disease Diseases 0.000 claims description 2
• 229960002170 azathioprine Drugs 0.000 claims description 2
• 229960002537 betamethasone Drugs 0.000 claims description 2
• UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
• 229960004436 budesonide Drugs 0.000 claims description 2
• 229960004544 cortisone Drugs 0.000 claims description 2
• 229960003957 dexamethasone Drugs 0.000 claims description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
• 229960000890 hydrocortisone Drugs 0.000 claims description 2
• 229960005294 triamcinolone Drugs 0.000 claims description 2
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 8
• 206010008190 Cerebrovascular accident Diseases 0.000 claims 4
• 208000026106 cerebrovascular disease Diseases 0.000 claims 4
• VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 1
• 108010035053 B7-1 Antigen Proteins 0.000 abstract description 4
• 102000038504 B7-1 Antigen Human genes 0.000 abstract description 4
• 102000007697 B7-2 Antigen Human genes 0.000 abstract description 4
• 108010021800 B7-2 Antigen Proteins 0.000 abstract description 4
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 224
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 224
• 230000000694 effects Effects 0.000 description 95
• 150000001413 amino acids Chemical group 0.000 description 67
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 58
• 230000027455 binding Effects 0.000 description 53
• 239000003446 ligand Substances 0.000 description 47
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 40
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 39
• 230000003907 kidney function Effects 0.000 description 37
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
• 239000003814 drug Substances 0.000 description 35
• 229940079593 drug Drugs 0.000 description 33
• 239000013598 vector Substances 0.000 description 33
• 206010063209 Chronic allograft nephropathy Diseases 0.000 description 32
• 201000001200 Crouzon syndrome-acanthosis nigricans syndrome Diseases 0.000 description 32
• 230000035772 mutation Effects 0.000 description 30
• 229940109239 creatinine Drugs 0.000 description 29
• 230000004083 survival effect Effects 0.000 description 27
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 26
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 26
• 230000008859 change Effects 0.000 description 26
• 201000010099 disease Diseases 0.000 description 26
• 238000002560 therapeutic procedure Methods 0.000 description 26
• 238000001802 infusion Methods 0.000 description 25
• 230000001506 immunosuppresive effect Effects 0.000 description 24
• 239000000203 mixture Substances 0.000 description 24
• 108090000623 proteins and genes Proteins 0.000 description 24
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 23
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 23
• 235000001014 amino acid Nutrition 0.000 description 23
• 229940024606 amino acid Drugs 0.000 description 23
• 230000003993 interaction Effects 0.000 description 22
• 238000001574 biopsy Methods 0.000 description 20
• 230000006870 function Effects 0.000 description 20
• 108020004705 Codon Proteins 0.000 description 19
• 208000021709 Delayed Graft Function Diseases 0.000 description 19
• 108010076504 Protein Sorting Signals Proteins 0.000 description 19
• 230000034994 death Effects 0.000 description 19
• 230000007774 longterm Effects 0.000 description 19
• 235000018102 proteins Nutrition 0.000 description 19
• 102000004169 proteins and genes Human genes 0.000 description 19
• 239000002131 composite material Substances 0.000 description 18
• 230000029142 excretion Effects 0.000 description 18
• 239000002773 nucleotide Substances 0.000 description 18
• 125000003729 nucleotide group Chemical group 0.000 description 18
• 238000002360 preparation method Methods 0.000 description 18
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 17
• 238000002703 mutagenesis Methods 0.000 description 17
• 231100000350 mutagenesis Toxicity 0.000 description 17
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 16
• 239000008194 pharmaceutical composition Substances 0.000 description 16
• 230000002829 reductive effect Effects 0.000 description 16
• 230000004044 response Effects 0.000 description 16
• 230000001900 immune effect Effects 0.000 description 15
• 239000003018 immunosuppressive agent Substances 0.000 description 15
• 208000032928 Dyslipidaemia Diseases 0.000 description 14
• 230000000781 anti-lymphocytic effect Effects 0.000 description 14
• 229940125721 immunosuppressive agent Drugs 0.000 description 14
• 230000002265 prevention Effects 0.000 description 14
• 238000011269 treatment regimen Methods 0.000 description 14
• 108020004414 DNA Proteins 0.000 description 13
• 229940046731 calcineurin inhibitors Drugs 0.000 description 13
• 230000002526 effect on cardiovascular system Effects 0.000 description 13
• 108020001507 fusion proteins Proteins 0.000 description 13
• 102000037865 fusion proteins Human genes 0.000 description 13
• 230000028993 immune response Effects 0.000 description 13
• 230000001965 increasing effect Effects 0.000 description 13
• 150000003431 steroids Chemical class 0.000 description 13
• 208000017170 Lipid metabolism disease Diseases 0.000 description 12
• 230000024924 glomerular filtration Effects 0.000 description 12
• 230000001404 mediated effect Effects 0.000 description 12
• 150000007523 nucleic acids Chemical class 0.000 description 12
• 238000003752 polymerase chain reaction Methods 0.000 description 12
• 230000009467 reduction Effects 0.000 description 12
• 230000000903 blocking effect Effects 0.000 description 11
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
• 206010012601 diabetes mellitus Diseases 0.000 description 11
• 230000006698 induction Effects 0.000 description 11
• 230000002980 postoperative effect Effects 0.000 description 11
• 238000012216 screening Methods 0.000 description 11
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 11
• 102100032937 CD40 ligand Human genes 0.000 description 10
• 206010062016 Immunosuppression Diseases 0.000 description 10
• 208000035475 disorder Diseases 0.000 description 10
• 230000002401 inhibitory effect Effects 0.000 description 10
• 230000005764 inhibitory process Effects 0.000 description 10
• 230000001105 regulatory effect Effects 0.000 description 10
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 9
• 108091028043 Nucleic acid sequence Proteins 0.000 description 9
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 9
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 9
• 235000018417 cysteine Nutrition 0.000 description 9
• 229960002963 ganciclovir Drugs 0.000 description 9
• IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 9
• 230000001771 impaired effect Effects 0.000 description 9
• 208000015181 infectious disease Diseases 0.000 description 9
• 238000001990 intravenous administration Methods 0.000 description 9
• 108020004707 nucleic acids Proteins 0.000 description 9
• 102000039446 nucleic acids Human genes 0.000 description 9
• 230000035935 pregnancy Effects 0.000 description 9
• 102000005962 receptors Human genes 0.000 description 9
• 108020003175 receptors Proteins 0.000 description 9
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 9
• 101150013553 CD40 gene Proteins 0.000 description 8
• 206010028980 Neoplasm Diseases 0.000 description 8
• 206010062237 Renal impairment Diseases 0.000 description 8
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 8
• WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 239000000427 antigen Substances 0.000 description 8
• 108091007433 antigens Proteins 0.000 description 8
• 102000036639 antigens Human genes 0.000 description 8
• 230000008614 cellular interaction Effects 0.000 description 8
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
• 238000010494 dissociation reaction Methods 0.000 description 8
• 230000005593 dissociations Effects 0.000 description 8
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 8
• 208000017169 kidney disease Diseases 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• 229960002149 valganciclovir Drugs 0.000 description 8
• 208000023275 Autoimmune disease Diseases 0.000 description 7
• 208000024172 Cardiovascular disease Diseases 0.000 description 7
• 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 7
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
• 229960004150 aciclovir Drugs 0.000 description 7
• MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 229940127088 antihypertensive drug Drugs 0.000 description 7
• 230000008901 benefit Effects 0.000 description 7
• 201000011510 cancer Diseases 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 230000007423 decrease Effects 0.000 description 7
• 238000011156 evaluation Methods 0.000 description 7
• 210000000987 immune system Anatomy 0.000 description 7
• 238000002650 immunosuppressive therapy Methods 0.000 description 7
• 230000006872 improvement Effects 0.000 description 7
• 210000000265 leukocyte Anatomy 0.000 description 7
• 230000002503 metabolic effect Effects 0.000 description 7
• 238000012544 monitoring process Methods 0.000 description 7
• 208000010125 myocardial infarction Diseases 0.000 description 7
• 230000035755 proliferation Effects 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• 238000012360 testing method Methods 0.000 description 7
• 230000001988 toxicity Effects 0.000 description 7
• 231100000419 toxicity Toxicity 0.000 description 7
• 241000196324 Embryophyta Species 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 6
• 108090000790 Enzymes Proteins 0.000 description 6
• 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 108010002350 Interleukin-2 Proteins 0.000 description 6
• 102000000588 Interleukin-2 Human genes 0.000 description 6
• 102000007330 LDL Lipoproteins Human genes 0.000 description 6
• 108010007622 LDL Lipoproteins Proteins 0.000 description 6
• 108010021466 Mutant Proteins Proteins 0.000 description 6
• 102000008300 Mutant Proteins Human genes 0.000 description 6
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
• 125000000539 amino acid group Chemical group 0.000 description 6
• 239000000969 carrier Substances 0.000 description 6
• 229940107810 cellcept Drugs 0.000 description 6
• 150000001875 compounds Chemical class 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 229940126534 drug product Drugs 0.000 description 6
• 239000013604 expression vector Substances 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 230000003589 nefrotoxic effect Effects 0.000 description 6
• 230000007170 pathology Effects 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 239000000825 pharmaceutical preparation Substances 0.000 description 6
• 231100000857 poor renal function Toxicity 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 6
• 238000011084 recovery Methods 0.000 description 6
• 230000028327 secretion Effects 0.000 description 6
• 239000000243 solution Substances 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 230000001225 therapeutic effect Effects 0.000 description 6
• 241000894006 Bacteria Species 0.000 description 5
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 5
• 208000005176 Hepatitis C Diseases 0.000 description 5
• 241000725303 Human immunodeficiency virus Species 0.000 description 5
• 230000006044 T cell activation Effects 0.000 description 5
• HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 208000020832 chronic kidney disease Diseases 0.000 description 5
• 230000003247 decreasing effect Effects 0.000 description 5
• 238000000502 dialysis Methods 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 230000014509 gene expression Effects 0.000 description 5
• 238000001631 haemodialysis Methods 0.000 description 5
• 210000002216 heart Anatomy 0.000 description 5
• 230000000322 hemodialysis Effects 0.000 description 5
• 208000002672 hepatitis B Diseases 0.000 description 5
• 230000002519 immonomodulatory effect Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 210000004962 mammalian cell Anatomy 0.000 description 5
• 230000004048 modification Effects 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 238000009597 pregnancy test Methods 0.000 description 5
• 230000010076 replication Effects 0.000 description 5
• 230000002441 reversible effect Effects 0.000 description 5
• 229940115586 simulect Drugs 0.000 description 5
• 238000001542 size-exclusion chromatography Methods 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 229940093257 valacyclovir Drugs 0.000 description 5
• 102000005738 B7 Antigens Human genes 0.000 description 4
• 108010045634 B7 Antigens Proteins 0.000 description 4
• -1 CD86 Proteins 0.000 description 4
• 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
• 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
• 206010018370 Glomerulonephritis membranoproliferative Diseases 0.000 description 4
• 208000004451 Membranoproliferative Glomerulonephritis Diseases 0.000 description 4
• 102000004140 Oncostatin M Human genes 0.000 description 4
• 108090000630 Oncostatin M Proteins 0.000 description 4
• 108010047620 Phytohemagglutinins Proteins 0.000 description 4
• 230000006052 T cell proliferation Effects 0.000 description 4
• 230000002776 aggregation Effects 0.000 description 4
• 238000004220 aggregation Methods 0.000 description 4
• 210000001185 bone marrow Anatomy 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 238000006243 chemical reaction Methods 0.000 description 4
• 238000011976 chest X-ray Methods 0.000 description 4
• 235000012000 cholesterol Nutrition 0.000 description 4
• 238000011260 co-administration Methods 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 230000000139 costimulatory effect Effects 0.000 description 4
• 230000016396 cytokine production Effects 0.000 description 4
• 230000006378 damage Effects 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 230000010247 heart contraction Effects 0.000 description 4
• 229940084986 human chorionic gonadotropin Drugs 0.000 description 4
• 208000025095 immunoproliferative disease Diseases 0.000 description 4
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
• NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 4
• 229960001025 iohexol Drugs 0.000 description 4
• 210000004185 liver Anatomy 0.000 description 4
• 230000036210 malignancy Effects 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 210000000885 nephron Anatomy 0.000 description 4
• 231100000381 nephrotoxic Toxicity 0.000 description 4
• 210000000496 pancreas Anatomy 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 230000001885 phytohemagglutinin Effects 0.000 description 4
• 239000000902 placebo Substances 0.000 description 4
• 229940068196 placebo Drugs 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 229920001184 polypeptide Polymers 0.000 description 4
• 102000004196 processed proteins & peptides Human genes 0.000 description 4
• 210000001236 prokaryotic cell Anatomy 0.000 description 4
• 229940099538 rapamune Drugs 0.000 description 4
• 150000003839 salts Chemical class 0.000 description 4
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 3
• 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 3
• 239000004475 Arginine Substances 0.000 description 3
• 108010029697 CD40 Ligand Proteins 0.000 description 3
• 241000283707 Capra Species 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 206010012735 Diarrhoea Diseases 0.000 description 3
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 3
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
• 102000001554 Hemoglobins Human genes 0.000 description 3
• 108010054147 Hemoglobins Proteins 0.000 description 3
• 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 3
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 3
• 102100025390 Integrin beta-2 Human genes 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• 108090000978 Interleukin-4 Proteins 0.000 description 3
• 208000032382 Ischaemic stroke Diseases 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
• RTGDFNSFWBGLEC-UHFFFAOYSA-N Mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 description 3
• 206010029155 Nephropathy toxic Diseases 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 230000020385 T cell costimulation Effects 0.000 description 3
• 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 3
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
• 239000004473 Threonine Substances 0.000 description 3
• 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 3
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 239000002671 adjuvant Substances 0.000 description 3
• 210000003484 anatomy Anatomy 0.000 description 3
• 210000004102 animal cell Anatomy 0.000 description 3
• 239000005557 antagonist Substances 0.000 description 3
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 230000036772 blood pressure Effects 0.000 description 3
• 230000001684 chronic effect Effects 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 238000013461 design Methods 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 210000003527 eukaryotic cell Anatomy 0.000 description 3
• 230000007717 exclusion Effects 0.000 description 3
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
• 201000005206 focal segmental glomerulosclerosis Diseases 0.000 description 3
• 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 description 3
• 229940028334 follicle stimulating hormone Drugs 0.000 description 3
• 230000002496 gastric effect Effects 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 208000024908 graft versus host disease Diseases 0.000 description 3
• 238000002657 hormone replacement therapy Methods 0.000 description 3
• 102000043321 human CTLA4 Human genes 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 201000001421 hyperglycemia Diseases 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 238000005304 joining Methods 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 238000009115 maintenance therapy Methods 0.000 description 3
• 235000012054 meals Nutrition 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 230000010534 mechanism of action Effects 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 239000000178 monomer Substances 0.000 description 3
• 231100000417 nephrotoxicity Toxicity 0.000 description 3
• 230000007694 nephrotoxicity Effects 0.000 description 3
• 229940126701 oral medication Drugs 0.000 description 3
• 230000003389 potentiating effect Effects 0.000 description 3
• 230000037452 priming Effects 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 238000002708 random mutagenesis Methods 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 238000010254 subcutaneous injection Methods 0.000 description 3
• 239000007929 subcutaneous injection Substances 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 229940107955 thymoglobulin Drugs 0.000 description 3
• 238000002562 urinalysis Methods 0.000 description 3
• WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 2
• 201000000736 Amenorrhea Diseases 0.000 description 2
• 206010001928 Amenorrhoea Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 241000713842 Avian sarcoma virus Species 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 241000701489 Cauliflower mosaic virus Species 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 108090000204 Dipeptidase 1 Proteins 0.000 description 2
• 108010024212 E-Selectin Proteins 0.000 description 2
• 102100023471 E-selectin Human genes 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 208000009693 Gingival Hyperplasia Diseases 0.000 description 2
• 244000068988 Glycine max Species 0.000 description 2
• 235000010469 Glycine max Nutrition 0.000 description 2
• 206010020112 Hirsutism Diseases 0.000 description 2
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
• 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
• 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
• 208000035150 Hypercholesterolemia Diseases 0.000 description 2
• 208000031226 Hyperlipidaemia Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 102100025304 Integrin beta-1 Human genes 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 229920001202 Inulin Polymers 0.000 description 2
• 108010092694 L-Selectin Proteins 0.000 description 2
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• 102000016551 L-selectin Human genes 0.000 description 2
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
• 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
• 206010025476 Malabsorption Diseases 0.000 description 2
• 208000004155 Malabsorption Syndromes Diseases 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
• 240000007594 Oryza sativa Species 0.000 description 2
• 235000007164 Oryza sativa Nutrition 0.000 description 2
• 208000028017 Psychotic disease Diseases 0.000 description 2
• 208000001647 Renal Insufficiency Diseases 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 101150052863 THY1 gene Proteins 0.000 description 2
• 241000702295 Tomato golden mosaic virus Species 0.000 description 2
• 206010066901 Treatment failure Diseases 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
• 240000008042 Zea mays Species 0.000 description 2
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 208000011930 active peptic ulcer disease Diseases 0.000 description 2
• 231100000540 amenorrhea Toxicity 0.000 description 2
• 239000012491 analyte Substances 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 239000002220 antihypertensive agent Substances 0.000 description 2
• 239000008365 aqueous carrier Substances 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 229940092117 atgam Drugs 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 102000006635 beta-lactamase Human genes 0.000 description 2
• 230000002146 bilateral effect Effects 0.000 description 2
• 238000009811 bilateral tubal ligation Methods 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 201000008275 breast carcinoma Diseases 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 208000019902 chronic diarrheal disease Diseases 0.000 description 2
• 229940047766 co-trimoxazole Drugs 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 230000001010 compromised effect Effects 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 230000004940 costimulation Effects 0.000 description 2
• 208000030381 cutaneous melanoma Diseases 0.000 description 2
• 238000007405 data analysis Methods 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 230000000779 depleting effect Effects 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 238000009093 first-line therapy Methods 0.000 description 2
• 229940044627 gamma-interferon Drugs 0.000 description 2
• 230000002414 glycolytic effect Effects 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 238000009802 hysterectomy Methods 0.000 description 2
• 230000036039 immunity Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 239000003838 injectable contraceptive agent Substances 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
• 229940029339 inulin Drugs 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
• 229960000310 isoleucine Drugs 0.000 description 2
• 201000006370 kidney failure Diseases 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 230000005906 menstruation Effects 0.000 description 2
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
• 238000000520 microinjection Methods 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 229940063121 neoral Drugs 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 238000009806 oophorectomy Methods 0.000 description 2
• 238000013146 percutaneous coronary intervention Methods 0.000 description 2
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
• 230000036470 plasma concentration Effects 0.000 description 2
• 238000002616 plasmapheresis Methods 0.000 description 2
• 238000013105 post hoc analysis Methods 0.000 description 2
• 230000001323 posttranslational effect Effects 0.000 description 2
• 230000009696 proliferative response Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• 210000001938 protoplast Anatomy 0.000 description 2
• 238000002271 resection Methods 0.000 description 2
• 235000009566 rice Nutrition 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 210000004927 skin cell Anatomy 0.000 description 2
• 235000002639 sodium chloride Nutrition 0.000 description 2
• 239000008354 sodium chloride injection Substances 0.000 description 2
• 229940074404 sodium succinate Drugs 0.000 description 2
• ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 230000001954 sterilising effect Effects 0.000 description 2
• 238000004659 sterilization and disinfection Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 201000009032 substance abuse Diseases 0.000 description 2
• 231100000736 substance abuse Toxicity 0.000 description 2
• 208000011117 substance-related disease Diseases 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 229940124597 therapeutic agent Drugs 0.000 description 2
• 229940113082 thymine Drugs 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 150000003626 triacylglycerols Chemical class 0.000 description 2
• 210000005239 tubule Anatomy 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 238000007879 vasectomy Methods 0.000 description 2
• 210000003462 vein Anatomy 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• ATOKJLVNLKSYTM-UHFFFAOYSA-N 3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;1-hydroxypyrrolidine-2,5-dione Chemical compound ON1C(=O)CCC1=O.CCN=C=NCCCN(C)C ATOKJLVNLKSYTM-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 208000009304 Acute Kidney Injury Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 241000589158 Agrobacterium Species 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 101710187573 Alcohol dehydrogenase 2 Proteins 0.000 description 1
• 101710133776 Alcohol dehydrogenase class-3 Proteins 0.000 description 1
• 244000144730 Amygdalus persica Species 0.000 description 1
• 102400000345 Angiotensin-2 Human genes 0.000 description 1
• 101800000733 Angiotensin-2 Proteins 0.000 description 1
• 208000004300 Atrophic Gastritis Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 102100036008 CD48 antigen Human genes 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• 229940122739 Calcineurin inhibitor Drugs 0.000 description 1
• 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 1
• 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 1
• 206010008909 Chronic Hepatitis Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
• 101710088194 Dehydrogenase Proteins 0.000 description 1
• 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 208000016937 Extranodal nasal NK/T cell lymphoma Diseases 0.000 description 1
• 238000001134 F-test Methods 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 208000036495 Gastritis atrophic Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 108010023302 HDL Cholesterol Proteins 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
• 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 206010019755 Hepatitis chronic active Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
• 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
• 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
• 101000992283 Homo sapiens Optineurin Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
• 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 241000701109 Human adenovirus 2 Species 0.000 description 1
• 206010020524 Hydronephrosis Diseases 0.000 description 1
• 206010020649 Hyperkeratosis Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
• 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
• 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
• 102100037850 Interferon gamma Human genes 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 241000483399 Ipimorpha retusa Species 0.000 description 1
• 108010025815 Kanamycin Kinase Proteins 0.000 description 1
• 241000235058 Komagataella pastoris Species 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 241001465754 Metazoa Species 0.000 description 1
• 208000019695 Migraine disease Diseases 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
• 239000004909 Moisturizer Substances 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 206010028665 Myxoedema Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 108091034117 Oligonucleotide Proteins 0.000 description 1
• 102100031822 Optineurin Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 108010087702 Penicillinase Proteins 0.000 description 1
• 102000007079 Peptide Fragments Human genes 0.000 description 1
• 108010033276 Peptide Fragments Proteins 0.000 description 1
• 208000031845 Pernicious anaemia Diseases 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 206010035226 Plasma cell myeloma Diseases 0.000 description 1
• 206010035660 Pneumocystis Infections Diseases 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 235000006040 Prunus persica var persica Nutrition 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 241000124033 Salix Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 230000017274 T cell anergy Effects 0.000 description 1
• 230000024932 T cell mediated immunity Effects 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 102100027208 T-cell antigen CD7 Human genes 0.000 description 1
• 206010042971 T-cell lymphoma Diseases 0.000 description 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 101710165202 T-cell surface antigen CD2 Proteins 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 206010070863 Toxicity to various agents Diseases 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
• 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 201000011040 acute kidney failure Diseases 0.000 description 1
• 208000012998 acute renal failure Diseases 0.000 description 1
• 229940086176 acyclovir 400 mg Drugs 0.000 description 1
• 238000001042 affinity chromatography Methods 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000000961 alloantigen Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• 229960000723 ampicillin Drugs 0.000 description 1
• AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
• 230000003872 anastomosis Effects 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 229950006323 angiotensin ii Drugs 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 229940121363 anti-inflammatory agent Drugs 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000010100 anticoagulation Effects 0.000 description 1
• 239000003524 antilipemic agent Substances 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 238000013475 authorization Methods 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 229940099090 basiliximab 20 mg Drugs 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 239000002981 blocking agent Substances 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 239000006143 cell culture medium Substances 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 235000019504 cigarettes Nutrition 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 238000003759 clinical diagnosis Methods 0.000 description 1
• 229940126523 co-drug Drugs 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 231100000026 common toxicity Toxicity 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 229940124301 concurrent medication Drugs 0.000 description 1
• 239000003636 conditioned culture medium Substances 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 239000002872 contrast media Substances 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 208000029078 coronary artery disease Diseases 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000007435 diagnostic evaluation Methods 0.000 description 1
• 230000035487 diastolic blood pressure Effects 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 208000028208 end stage renal disease Diseases 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000037433 frameshift Effects 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 230000030136 gastric emptying Effects 0.000 description 1
• 238000005227 gel permeation chromatography Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000003494 hepatocyte Anatomy 0.000 description 1
• 102000054189 human CD80 Human genes 0.000 description 1
• 102000049849 human CD86 Human genes 0.000 description 1
• 208000006575 hypertriglyceridemia Diseases 0.000 description 1
• 229940124622 immune-modulator drug Drugs 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 229940073062 imuran Drugs 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 238000011419 induction treatment Methods 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 235000013902 inosinic acid Nutrition 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 229960000318 kanamycin Drugs 0.000 description 1
• 229930027917 kanamycin Natural products 0.000 description 1
• SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
• 229930182823 kanamycin A Natural products 0.000 description 1
• 238000009533 lab test Methods 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 238000011545 laboratory measurement Methods 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
• 231100001231 less toxic Toxicity 0.000 description 1
• 150000002614 leucines Chemical class 0.000 description 1
• 230000021633 leukocyte mediated immunity Effects 0.000 description 1
• 201000002364 leukopenia Diseases 0.000 description 1
• 231100001022 leukopenia Toxicity 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000012669 liquid formulation Substances 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 230000008376 long-term health Effects 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 239000003120 macrolide antibiotic agent Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 235000009973 maize Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 238000010297 mechanical methods and process Methods 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229940005028 methylprednisolone 500 mg Drugs 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 206010027599 migraine Diseases 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 229950000844 mizoribine Drugs 0.000 description 1
• 230000001333 moisturizer Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 229940083410 myfortic Drugs 0.000 description 1
• 208000003786 myxedema Diseases 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 230000007896 negative regulation of T cell activation Effects 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100001210 nonnephrotoxic Toxicity 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 238000007410 oral glucose tolerance test Methods 0.000 description 1
• 229940029358 orthoclone okt3 Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 238000004223 overdiagnosis Methods 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 229950009506 penicillinase Drugs 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 238000011458 pharmacological treatment Methods 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000009117 preventive therapy Methods 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 229940072288 prograf Drugs 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 230000000644 propagated effect Effects 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 239000013636 protein dimer Substances 0.000 description 1
• 238000000751 protein extraction Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000012121 regulation of immune response Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000000250 revascularization Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000012502 risk assessment Methods 0.000 description 1
• 229940063122 sandimmune Drugs 0.000 description 1
• 230000037390 scarring Effects 0.000 description 1
• 239000002412 selectin antagonist Substances 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 230000037432 silent mutation Effects 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 210000003491 skin Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 238000007614 solvation Methods 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 239000008227 sterile water for injection Substances 0.000 description 1
• 238000012916 structural analysis Methods 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000035488 systolic blood pressure Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000005026 transcription initiation Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 238000000844 transformation Methods 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229960001082 trimethoprim Drugs 0.000 description 1
• IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 239000010937 tungsten Substances 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229940035893 uracil Drugs 0.000 description 1
• 210000001635 urinary tract Anatomy 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 238000003260 vortexing Methods 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000011240 wet gel Substances 0.000 description 1